Get the Stockscreener App
3.05
1.93%
-0.06
Envveno Medical Corporation stock is traded at $3.05, with a volume of 68,598.
It is down -1.93% in the last 24 hours and down -10.03% over the past month.
enVVeno Medical Corp is a medical device company focused on the development of bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).
See More
Previous Close:
$3.11
Open:
$3.13
24h Volume:
68,598
Relative Volume:
0.50
Market Cap:
$54.54M
Revenue:
-
Net Income/Loss:
$-24.05M
P/E Ratio:
-1.4186
EPS:
-2.15
Net Cash Flow:
$-17.78M
1W Performance:
-7.29%
1M Performance:
-10.03%
6M Performance:
-38.63%
1Y Performance:
-30.68%
1-Day Range:
$3.05
$3.3134
1-Week Range:
$3.05
$3.3731
52-Week Range:
$2.45
$6.97
Envveno Medical Corporation Stock (NVNO) Company Profile
Name
Envveno Medical Corporation
Sector
Industry
Phone
949-261-2900
Address
70 DOPPLER, IRVINE
Compare NVNO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVNO
Envveno Medical Corporation
|
3.05 | 54.54M | 0 | -24.05M | -17.78M | -2.15 |
|
ABT
Abbott Laboratories
|
129.16 | 222.39B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
105.22 | 154.78B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
391.08 | 150.99B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
89.64 | 116.46B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
70.63 | 41.87B | 6.60B | 4.16B | 490.10M | 6.93 |
Envveno Medical Corporation Stock (NVNO) Latest News
VenoValve trial shows sustained patient benefits at 24 months - Investing.com India
Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting - Weatherford Democrat
VenoValve Clinical Trial Hits Home Run: 100% Patency Rate Stuns Medical Community - StockTitan
enVVeno Medical to Present at the Virtual Investor 2022 Top Picks Conference - ACCESS Newswire
enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity - ACCESS Newswire
enVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve(R) - ACCESS Newswire
Westside Investment Management Inc. Acquires 116,650 Shares of enVVeno Medical Corporation (NASDAQ:NVNO) - MarketBeat
Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth - Yahoo Finance
enVVeno Medical Corporation (NASDAQ:NVNO) Shares Bought by Geode Capital Management LLC - Defense World
Hancock Jaffe Laboratories, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019 - Marketscreener.com
enVVeno Medical (NASDAQ:NVNO) and Sharps Technology (NASDAQ:STSS) Head to Head Survey - Defense World
Insider Buying: Francis Duhay Acquires Shares of enVVeno Medical Corp - GuruFocus.com
Envveno medical director Robert Gray buys $10,290 in shares - Investing.com India
Envveno medical director Duhay Francis buys $249,999 in stock By Investing.com - Investing.com Canada
Envveno medical director Robert Gray buys $10,290 in shares By Investing.com - Investing.com Australia
Envveno medical director Duhay Francis buys $249,999 in stock - Investing.com India
Insider Buying: Robert Gray Acquires 3,500 Shares of enVVeno Med - GuruFocus.com
enVVeno Medical Corporation (NASDAQ:NVNO) Director Purchases $10,290.00 in Stock - MarketBeat
Insider Buying: Sanjay Shrivastava Acquires Shares in enVVeno Me - GuruFocus.com
enVVeno Medical Corporation (NASDAQ:NVNO) Director Acquires $15,660.00 in Stock - MarketBeat
Envveno Medical's director Sanjay Shrivastava buys $15,660 in stock - Investing.com
Insider Buying: Matthew Jenusaitis Acquires 9,620 Shares of enVV - GuruFocus.com
Envveno medical director Matthew Jenusaitis buys $24,338 in stock By Investing.com - Investing.com Nigeria
Envveno medical director Matthew Jenusaitis buys $24,338 in stock - Investing.com India
Critical Survey: enVVeno Medical (NASDAQ:NVNO) versus Profound Medical (NASDAQ:PROF) - Defense World
NVNO stock touches 52-week low at $2.5 amid market challenges By Investing.com - Investing.com South Africa
NVNO stock touches 52-week low at $2.5 amid market challenges - Investing.com
Envveno Medical CEO Robert Berman acquires $30,599 in stock By Investing.com - Investing.com Australia
CEO Robert Berman Increases Stake in enVVeno Medical Corp with R - GuruFocus.com
Envveno Medical CEO Robert Berman acquires $30,599 in stock - Investing.com
enVVeno Medical completes final wave of implants in pre-clinical GLP study - TipRanks
enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe - AccessWire
enVVeno Medical Completes Key Pre-Clinical Study for Revolutionary Venous Valve, Advances FDA Approval Path - StockTitan
NVNO Stock Touches 52-Week Low at $2.9 Amid Market Challenges - Investing.com
NVNO Stock Touches 52-Week Low at $3.01 Amid Market Challenges - Investing.com
enVVeno launches recap website highlighting VEITH Symposium participation - TipRanks
enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website - Kansas City Star
enVVeno Medical Showcases Breakthrough VenoValve Trial Data at VEITH Symposium | NVNO Stock News - StockTitan
NVNO Completes Application for VenoValve's PMA, Shares Likely to Gain - MSN
enVVeno Medical (NASDAQ:NVNO) Is In A Good Position To Deliver On Growth Plans - Simply Wall St
Reviewing enVVeno Medical (NASDAQ:NVNO) and Cerus (NASDAQ:CERS) - Defense World
PMA application submitted for VenoValve device - Venous News
enVVeno Medical (STU:5HJ) Profitability Rank : 1 (As of Sep. 2024) - GuruFocus.com
enVVeno Medical rises on submission of the venovalve PMA application for FDA approval - MSN
One-year data from the VenoValve US pivotal trial emerge - Venous News
Envveno Medical Corporation Stock (NVNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Envveno Medical Corporation Stock (NVNO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gray Robert | Director |
Dec 31 '24 |
Buy |
2.94 |
3,500 |
10,290 |
11,155 |
| Shrivastava Sanjay | Director |
Dec 24 '24 |
Buy |
2.90 |
5,400 |
15,660 |
9,288 |
| Jenusaitis Matthew | Director |
Dec 19 '24 |
Buy |
2.53 |
9,620 |
24,339 |
16,545 |
| BERMAN ROBERT ANDREW | Chief Executive Officer |
Dec 19 '24 |
Buy |
2.55 |
12,000 |
30,600 |
222,236 |
| Alavi Hamed | Chief Technology Officer |
Mar 13 '24 |
Option Exercise |
3.59 |
8,334 |
29,919 |
8,334 |
| Alavi Hamed | Chief Technology Officer |
Mar 13 '24 |
Sale |
6.22 |
8,334 |
51,837 |
0 |
1.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):